IMV Inc. (TSX: IMV), a clinical-stage biopharmaceutical company developing a novel class of cancer vaccines, along with certain related companies, obtained protection under the CCAA on May 1. Based in Dartmouth, Nova Scotia, the company has not generated any revenue from product sales and its cumulative losses total $261.2 million. While under creditor protection, the company will look to complete one or more transactions that will allow its technology to continue to be developed in the hope that it can one day change the lives of patients with cancer. FTI was appointed monitor. Counsel is McCarthy Tétrault and Stewart McKelvey for the company, Aird & Berlis for secured creditor Horizon Technology Finance Corporation and Stikeman Elliott for the monitor.